Skip to main content
. 2020 May 7;12(9):8221–8240. doi: 10.18632/aging.103135

Figure 1.

Figure 1

R406 reduces viability of senescent HDFs. Senescent HDFs (HDF-Old) and non-senescent HDFs (HDF-Young) were treated with (A) R406 (1, 2, 5, 10, 20 μM), (B) Nintedanib (1, 2, 5, 10, 20 μM), (C) AZD (0.5, 1, 5, 10, 20 μM), (D) NVP-BHG712 (0.5, 1, 5, 10, 20 μM), (E) CCT129202 (0.5, 1, 5, 10, 20 μM), and (F) Axitinib (1, 2, 5, 10, 20 μM) for one day, and then CCK-1 assays were conducted to investigate cell viability. n = 8, *p<0.05, **p<0.01, ***P<0.001.